Implications of the outcome of EMPA-REG outcome on type 2 diabetes mellitus management

  • Dr. Manoj Gogoi Rontix Hospital, National Highway 37, At Road Margherita Tinsukia -786181
  • Dr. Karthik N Saslu Consultant Physician, Saslu Clinic, 2nd Main, 4th Cross, PJ Extension Davangere, 577002
  • Dr. Pankaj Kumar Tanisha Clinic, Parsudih, Jamshedpur-831002
  • Dr. Partha Pratim Kalita Endocrinology and Diabetes, Bhabananda Boro path, Ahom gaon, Gorchuk, Guwahati 781035
  • Dr. Chetan Patil Consultant Physician, Mukati Hospital Plot No.11, Shivaji Nagar Nashik-Pune Road, Nashik-422006
Keywords: Cardiovascular disease, Type 2 diabetes, Hypoglycaemia, Sodium-glucose co-transporter-2 (SGLT2) inhibitor, Glycaemic control

Abstract

Diabetes has been implicated in micro-and macro-vascular complications. Glycaemic controls have been found to reduce the risk of microvascular complications in type 2 diabetes. However, studies suggest a possible relation between glycaemic control in decreasing macrovascular complications. The traditional approach of aggressive glycaemic management often leads to hypoglycaemia. Hypoglycaemia induces a series of physiological effects that increase cardiovascular disease risk (CVD). In fact, most of the hypoglycaemic agents such as thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose cotransporter 2 (SGLT2) inhibitors have been approved based on their ability to decrease glycosylated haemoglobin A1c (HbA1c) rather than their ability to prevent CV morbidity and mortality. In the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients Removing Excess Glucose (EMPA-REG OUTCOME®) trial, Empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, have been proven to exert a cardioprotective effect in type 2 diabetes patients. This paper discusses the outcome of EMPA-REG OUTCOME® and its implication in the management of type 2 diabetes patients that are at risk for CVD.

Downloads

Download data is not yet available.

References

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2016;374(11):1092-1094. doi:10.1056/NEJMc1600827

Strojek K, Rokicka D, Szymborska-Kajanek A, Wróbel M. Empagliflozin. Results of the EMPA-REG OUTCOME trial. A breakthrough in the treatment of type 2 diabetes? Clinical Diabetology. 2016;5(3):107-110. doi:10.5603/DK.2016.0018

Desouza C v., Bolli GB, Fonseca V. Hypoglycemia, Diabetes, and Cardiovascular Events. Diabetes Care. 2010;33(6):1389-1394. doi:10.2337/dc09-2082

Snell-Bergeon JK, Wadwa RP. Hypoglycemia, Diabetes, and Cardiovascular Disease. Diabetes Technology & Therapeutics. 2012;14(S1): S-51-S-58. doi:10.1089/ dia.2012.0031

Fitchett D, Inzucchi SE, Wanner C, et al. Relationship between hypoglycemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOMEVR trial. European Heart Journal. 2020;41(2):209-217. doi:10.1093/eurheartj/ehz621

Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Research and Clinical Practice. 2014;104(3):297-322. doi: 10.1016/j.diabres.2014.02.014

Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. The Lancet Diabetes & Endocrinology. 2013;1(2):140-151. doi:10.1016/S2213-8587(13)70050-0

Bays H. Sodium-Glucose Cotransporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. Diabetes Therapy. 2013;4(2):195-220. doi:10.1007/s13300-013-0042-y

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2016;374(11):1092-1094. doi:10.1056/NEJMc1600827

Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine. 2016;375(4):323-334. doi:10.1056/NEJMoa1515920

Perreault L. EMPA-REG OUTCOME: The Endocrinologist's Point of View. The American Journal of Medicine. 2017;130(6): S51-S56. doi: 10.1016/j.amjmed.2017.04.005

Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care. 2016;39(7):1108-1114. doi:10.2337/dc16-0330

CITATION
DOI: 10.26838/MEDRECH.2022.9.2.585
Published: 2022-04-15
How to Cite
1.
Gogoi M, Saslu KN, Kumar P, Kalita PP, Patil C. Implications of the outcome of EMPA-REG outcome on type 2 diabetes mellitus management. Med. res. chronicles [Internet]. 2022Apr.15 [cited 2022May22];9(2):94-8. Available from: https://medrech.com/index.php/medrech/article/view/568
Section
Original Research Article